Chinmay Jani, MD, highlights non-smoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.
News|Videos|December 4, 2023
Optimizing EGFR-Mutant NSCLC Care: Future Directions
Closing insights into managing EGFR-mutant NSCLC, from evolving treatment options and sequencing strategies to addressing unmet needs and the importance of comprehensive genomic testing.
Advertisement
Advertisement
Related to this article
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Presentations at ESMO Congress 2026 detailed how surgery, radiation oncology, and supportive care can contribute to the treatment of patients with NSCLC.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
Advertisement
Advertisement
Trending on CancerNetwork
1
Closing the Gaps in Precision Oncology for Breast Cancer
2
KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer
3
Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges
4
Managing Patients With No Pathologic Response After Durvalumab Plus FLOT
5